A Capital Analysis On China’s Health Care Mergers And Acquisitions
This article was originally published in PharmAsia News
Government, private and foreign funds look set to be the three main cornerstones that shape China's health care market. According to industry analysis from 2004 - 2006, domestic capital led with a higher-than-expected 86 percent of the total mergers and acquisitions amount, way ahead of the 14 percent from foreign companies, even though the latter showed continuous growth. Out of the local monies injected into mergers and acquisitions, the 47 percent from the private sector overtook state-owned funding of 39 percent. Private investors have clear acquisition targets and strategies, while state-linked enterprises' pursuits are often influenced by the government. Compared with domestic funding, foreign investment offers unmatched advantages such as substantial capital, advanced technologies, reliable product quality, effective management and wealth of experience. (Click here for more - Chinese language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.